Scale -


  • Revenue is 6929 Rs Cr; Continuous Growth over 3 years
  • Ebitda is 2180 Rs Cr; Continuous Growth over 3 years; 5 Year CAGR is 17 %
  • PBT is 572 Rs Cr; Continuous Growth over 3 years; 5 Year CAGR is 18 %
  • PAT is 1552 Rs Cr; Continuous Growth over 3 years; 5 Year CAGR is 18 %
  • Quarterly Ebitda is 522 Rs Cr; Continuous Growth over 3 Quarters

Profitability -


  • PBDIT Margin is 31.46 %; Continuous Growth over 3 years
  • PAT Margin is 22.39 %; Continuous Growth over 3 years; in Top Quartile; 5 Year CAGR is 8 %
  • Quarterly Ebitda Margin is 29 %; Continuous Growth over 3 Quarters; in Top Quartile
  • Quarterly Profit margin is 24 %; Continuous Growth over 3 Quarters; in Top Quartile

Return -


  • ROCE is 41.87 %; in Top Quartile; Continuous Decline over 3 years
  • ROA is 23.87 %; in Top Quartile
  • ROE is 32.5 %; in Top Quartile
  • Asset Turnover is 112 %; in Top Quartile; Continuous Decline over 3 years

Efficiency -


  • Operating cash flow is 1319 Rs Cr; Annual Growth is 30 %
  • Inventory Turnover Ratio is 7.58; in Top Quartile; 5 Year CAGR is 81 %; Continuous Decline over 3 years
  • Quick Ratio is 1.91; Annual Decline is -31 %

Solvancy -


  • Debt/Equity is 0; in Bottom Quartile
  • Total Debt is 0 Rs Cr; in Bottom Quartile
  • Contingent Liabilities is 116 Rs Cr; in Bottom Quartile; Continuous Growth over 3 years

Quality -


  • Other Expenses/Total Expenses is 13 %; in Bottom Quartile
  • Change in Inventories/Total Expenses is -2 %; Annual Growth is 56 %
  • Exceptional Items/PBT is 0 %; in Top Quartile

Quarterly Results- overall

Annual Results- Scale

Annual Results- Liquidity

Annual Results- Profitability/Return

Annual Results- Valuation

External Ecosystem


Sector
Major Subsidiaries/Associates
Key Clients

Products


Products
Product details

Operations


Capacity/ Production
Key Facilities
Key Certifications
Raw materials
Recent News
Abbott India Limited (ABBOTINDIA.NS) Seasonal returns chart
Abbott India (NSEI:ABBOTINDIA)
Top 14 Pharma Stocks To Buy In India October 2026
Indian shares extend losses as high oil prices heighten inflation worries
Nestle, Zydus, Abbott face India scrutiny over claims on children's products
ABBOTINDIA Outlook for the Week